Spinocerebellar Degenerations

Slide 1 · Spinocerebellar

Degenerations

Neurodegeneration across cerebellar, spinal, and peripheral systems

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Define the common tissue targets and clinical heterogeneity of spinocerebellar degenerations.

Distinguish dominant SCAs from Friedreich ataxia and ataxia-telangiectasia.

Compare coding-repeat, noncoding-repeat, and conventional SCA mutations.

Connect FXN and ATM abnormalities to their characteristic clinical syndromes.

Slide 3 · One umbrella: Three vulnerable systems

Cerebellum

Neuronal dysfunction and loss contribute to disordered coordination.

Spinal cord

Degeneration contributes to motor and sensory manifestations.

Peripheral nerves

Nerve involvement can add weakness, impaired sensation, and reflex changes.

The commonality is anatomic vulnerability—not one shared molecular cause.

Slide 4 · Definition: A heterogeneous degenerative group

Shared pathology: Neuronal loss and dysfunction in cerebellum, spinal cord, and peripheral nerves.

The group spans distinct genotypes, ages at onset, and clinical presentations.

Classification increasingly follows genetic analysis rather than appearance alone.

Anatomical convergence does not imply genetic uniformity.

Slide 5 · Heterogeneity occurs along three axes

Genetic etiology

Dominant SCA families; Recessive Friedreich ataxia and ataxia-telangiectasia.

Age at onset

Childhood-onset syndromes coexist with disorders having variable onset.

Clinical syndrome

Ataxia may be accompanied by sensory, motor, ocular, cardiac, or immune findings.

Slide 6 · Anatomical involvement explains clinical overlap

Cerebellar dysfunction makes ataxia a common presenting theme.

Spinal and peripheral nerve injury broadens the syndrome beyond isolated ataxia.

Similar motor findings may therefore arise from different inherited diseases.

Extraneural manifestations may point toward particular etiologies.

Slide 7 · A genetically useful first division

Dominant group

Spinocerebellar ataxias: A large group of autosomal-dominant inherited degenerations.

Recessive group A

Friedreich ataxia: Progressive ataxia with neuropathy and cardiomyopathy.

Recessive group B

Ataxia-telangiectasia: Childhood ataxia with telangiectasias and immunodeficiency.

Slide 8 · A shared syndrome is not one disease

Phenotypic overlap is substantial despite distinct causal lesions.

Molecular categories organize the SCAs more effectively than ataxia alone.

Friedreich ataxia exemplifies mitochondrial dysfunction from reduced frataxin.

Ataxia-telangiectasia links neurodegeneration with impaired DNA-damage signaling.

Slide 9 · What a neuropathologist should infer—and not infer

Supported finding

Neuronal loss and dysfunction affect multiple connected neural compartments.

Reasonable interpretation

Multisystem injury can produce combinations of gait, limb, reflex, and sensory abnormalities.

Not established

A single microscopic signature or unified lesion explains all disorders.

Distinguish the textbook’s shared localization from a universal histologic pattern.

Slide 10 · Molecular diagnosis changes classification

More than 40 SCA subtypes are distinguished through genetic, clinical, and pathologic information.

Genetic causes have been found for more than half of these SCA entities.

This progress in classification has not produced complete mechanistic understanding.

No corresponding universal effective treatments.

Slide 11 · Spinocerebellar ataxias: Defined by inheritance

“SCA” denotes a family of autosomal-dominant inherited spinocerebellar degenerations.

The term encompasses many distinct genotypes rather than a single mutation.

Molecular mechanisms and accompanying clinical findings vary across types.

Slide 12 · SCA classification is multidimensional

Genetic

Causative variant or repeat-expansion locus.

Clinical

Ataxia plus subtype-associated neurological or other findings.

Pathologic

Patterns of nervous-system degeneration and cellular involvement.

Slide 13 · More than 40 SCA subtypes

More than 40 molecularly and clinicopathologically defined subtypes.

A numbered SCA designation identifies a distinct genetically characterized category.

Subtype diversity prevents a single genotype–phenotype description from covering all SCAs.

Use the SCA number together with a genetic mechanism—not as an explanation by itself.

Slide 14 · Three classes of SCA mutations

Coding CAG expansions

Translated polyglutamine tracts; Proteins accumulate in neuronal nuclear inclusions.

Noncoding repeat expansions

Expanded repeats outside protein-coding sequences; Disease mechanism remains unclear.

Conventional mutations

Copy-number changes, deletions, insertions, and point mutations affect diverse proteins.

Slide 15 · Coding expansion: Repeat to protein

DNA sequence

Expansion of a coding CAG tract

Protein

Extended glutamine tract (“polyQ”)

Cellular finding

Mutant proteins accumulate as neuronal nuclear inclusions

Protein inclusion formation as a hallmark, not proof of one injury pathway.

Slide 16 · Why CAG expansion changes the protein

A CAG triplet encodes the amino acid glutamine.

When expanded within a coding sequence, it produces an elongated polyglutamine tract.

The affected protein is mutant despite retention of its broader protein identity.

Accumulation of this protein can be demonstrated as nuclear inclusions.

Slide 17 · Polyglutamine inclusions: Correct interpretation

The source reports nuclear inclusion accumulation in the relevant SCA variants.

The inclusion pattern suggests mechanisms analogous to Huntington disease.

It does not identify the precise toxic step or establish inclusions as the sole cause.

Slide 18 · Polyglutamine SCA spectrum: Named examples

SCA1, SCA2

Both are classified among CAG/polyglutamine-associated SCAs.

SCA3, SCA6

Both are also included in the polyglutamine class.

SCA7, SCA8, SCA17

Listed in the Robbins polyglutamine group; SCA7 has visual impairment.

Slide 19 · Machado–Joseph disease corresponds to SCA3

Spinocerebellar ataxia type 3 as Machado–Joseph disease.

It belongs in the group associated with coding CAG expansion and polyglutamine.

The synonym is a disease-name correspondence, not a separate mechanistic category.

Slide 20 · SCA7: Visual impairment is a useful clue

SCA7 is included among the polyglutamine spinocerebellar ataxias.

Visual impairment as a relatively distinguishing feature.

A visual complaint can help refine the pattern of an otherwise ataxic syndrome.

Slide 21 · Polyglutamine disorders extend beyond numbered SCAs

Dentatorubral-pallidoluysian atrophy (DRPLA) in the polyglutamine disease group.

This classification is mechanistic; DRPLA is not itself a numbered SCA subtype.

Shared repeat chemistry can link disorders that differ in clinical designation.

Slide 22 · Polyglutamine SCAs versus Huntington disease

Common molecular motif

A coding CAG repeat expansion leads to a polyglutamine-containing mutant protein.

Common cellular theme

Abnormal proteins accumulate; Nuclear inclusion patterns are reported.

Distinct clinical entities

Huntington disease and SCAs differ in dominant neuroanatomic and clinical manifestations.

Slide 23 · Noncoding repeat expansions: What is known

DNA repeat

Repeat expands outside protein-coding sequence

Inherited SCA

Specific loci are associated with disease

Mechanism

Exact causal molecular steps remain unresolved

Do not depict an unproven toxic RNA/protein mechanism as established for all subtypes.

Slide 24 · Six noncoding-repeat SCAs

SCA10 • SCA12

Explicitly assigned to the noncoding-repeat class.

SCA27B • SCA31

Explicitly assigned to the noncoding-repeat class.

SCA36 • SCA37

Explicitly assigned to the noncoding-repeat class.

Slide 25 · Known locus does not mean known mechanism

For most noncoding-repeat SCAs, the implicated genetic locus has been defined.

The causal steps connecting repeat expansion to degeneration are not established in the source.

Do not infer that every noncoding expansion acts through an identical toxic product.

Slide 26 · Coding versus noncoding expansions

Coding CAG repeats

Translated into expanded polyglutamine tracts within mutant proteins.

Noncoding repeats

Disease-associated expansions without the same direct polyglutamine coding mechanism.

Both are repeat-expansion diseases, but their demonstrated molecular consequences differ.

Slide 27 · Conventional SCA mutations: Variant classes

Copy-number variation alters the number of copies of a genetic segment.

Deletions remove DNA sequence; Insertions add sequence.

Point mutations change individual sequence positions.

Robbins groups the remaining SCAs under these conventional mutation mechanisms.

Slide 28 · Affected protein pathways in conventional SCAs

Receptors

Altered signaling at cellular reception or transduction steps.

Ion channels

Altered proteins involved in membrane electrical signaling.

Kinases

Altered proteins participating in signal-transduction cascades.

These are protein categories named; No specific variant–channel pairing is implied.

Slide 29 · Three SCA mutation classes compared

Feature

Coding CAG

Noncoding repeats

Conventional variants

Primary lesion

Coding triplet expansion

Expansion outside coding tract

CNV / indel / point mutation

Protein consequence

Expanded polyglutamine

Not a common direct polyQ mechanism

Diverse signaling proteins affected

Source mechanism

Intranuclear mutant protein

Unclear

Altered receptors / channels / kinases

Slide 30 · What genetic classification can establish

A specific SCA locus or mutation can define the inherited disease category.

Mutation class gives a mechanistic starting point for biological interpretation.

A genetic label alone does not specify an exact age at onset or clinical course.

Across SCAs, causal cellular cascades remain incompletely resolved.

Slide 31 · Avoid overinterpreting nuclear inclusions

Nuclear accumulation is reported in the polyglutamine SCA group.

The finding supports abnormal processing or persistence of mutant protein.

It does not demonstrate that every SCA subtype has such inclusions.

A conventional mutation or noncoding expansion should not be equated with polyQ pathology.

Slide 32 · Friedreich ataxia: Autosomal-recessive degeneration

Friedreich ataxia is recessively inherited, unlike the dominant SCA group.

Its syndrome includes progressive ataxia, weakness, spasticity, and sensory neuropathy.

Cardiomyopathy makes the disease systemically consequential.

Slide 33 · Friedreich ataxia: Typical clinical sequence

Early childhood

Gait ataxia, often beginning in the first decade

Progression

Hand clumsiness and dysarthria follow

Broader disability

Motor, sensory, and systemic complications accumulate

Slide 34 · Motor examination contains mixed signs

Progressive weakness and spasticity contribute to motor disability.

Deep tendon reflexes are reduced or absent.

An extensor plantar response is nevertheless typically present.

The juxtaposition reflects involvement beyond a pure peripheral neuropathy.

Slide 35 · Why the reflex pattern is diagnostically instructive

Depressed reflexes

Compatible with damage to the afferent or peripheral components of the reflex arc.

Extensor plantar response

Suggests dysfunction of descending motor pathways.

Both findings may coexist in a single multisystem neurodegenerative condition.

Slide 36 · Sensory examination: Proprioception is prominent

Joint-position sense is impaired.

Vibratory sense is impaired.

Pain, temperature, and light touch may also be reduced in some patients.

Sensory abnormalities contribute to the complexity of the ataxic syndrome.

Slide 37 · Friedreich ataxia: Orthopaedic associations

Pes cavus

A high-arched foot is a commonly observed deformity.

Kyphoscoliosis

Spinal curvature can arise as the neurological illness progresses.

Slide 38 · Cardiomyopathy is a major determinant of outcome

Friedreich ataxia is accompanied by cardiomyopathy.

Arrhythmias and congestive heart failure occur with high frequency.

Cardiac disease as contributing to many deaths.

Cardiac manifestations distinguish this syndrome from isolated cerebellar dysfunction.

Slide 39 · Diabetes is an associated systemic feature

Concomitant diabetes in up to one quarter of affected individuals.

This is a reported association, not a universal diagnostic criterion.

An ataxia syndrome accompanied by cardiac and metabolic disease warrants a systemic framework.

Slide 40 · Friedreich ataxia: Neurological and systemic domains

Neurological

Gait and limb ataxia; Weakness; Spasticity; Dysarthria; Sensory loss.

Skeletal

Pes cavus and kyphoscoliosis in many affected people.

Systemic

Cardiomyopathy and associated diabetes.

Slide 41 · Course and prognosis in the supplied Robbins text

The source describes a relentlessly progressive loss of mobility.

It reports that many affected people require a wheelchair within roughly five years of onset.

It describes a typical life expectancy limited to approximately 40–50 years.

These are textbook-level generalizations, not individualized prognostic predictions.

Slide 42 · FXN intronic expansion: From DNA to expression

FXN gene

Expansion of a GAA repeat in intron 1

Chromatin

Repeat-associated structural changes in chromatin

Expression

Reduced production of frataxin protein

Slide 43 · The FRDA mutation is noncoding—but distinct from SCAs

Friedreich ataxia involves GAA expansion in the first intron of FXN.

The gene lies on chromosome 9 in the supplied source.

The expansion lowers frataxin expression through altered chromatin structure.

“Noncoding expansion” describes mutation location; It does not place FRDA among dominant SCAs.

Slide 44 · Frataxin and the mitochondrion

Protein identity

Frataxin is a mitochondrial protein encoded by FXN.

Functional role

It participates in assembly of iron–sulfur cluster enzymes.

Affected systems

Mitochondrial complexes I and II.

Slide 45 · Reduced frataxin compromises bioenergetics

Reduced frataxin

Lower abundance of the mitochondrial protein

Iron–sulfur enzymes

Disturbed assembly of relevant respiratory proteins

Consequences

Reduced oxidative phosphorylation and excess free iron

Slide 46 · Iron accumulation adds a potential injury mechanism

Reduced frataxin is associated with increased mitochondrial free iron.

Free iron can contribute to oxidative stress.

The textbook links oxidative phosphorylation deficiency and oxidative stress as consequences.

It does not quantify the individual contribution of each pathway to neurodegeneration.

Slide 47 · Friedreich ataxia has two reported genotypes

Common configuration

GAA-repeat expansion present in both FXN alleles.

Less common configuration

Expansion in one allele with a loss-of-function point mutation in the other.

Both configurations are compatible with recessive disease.

Slide 48 · A unified pathogenesis for Friedreich ataxia

An inherited FXN lesion reduces expression of mitochondrial frataxin.

Iron–sulfur enzyme assembly and respiratory-chain function become impaired.

Oxidative metabolism deteriorates while free iron may amplify cellular stress.

These cellular disturbances accompany progressive neurological and systemic illness.

Slide 49 · Ataxia-telangiectasia: A multisystem recessive syndrome

Ataxia-telangiectasia is autosomal recessive.

Childhood ataxia and dyskinesia coexist with telangiectasias and immunodeficiency.

DNA-damage response dysfunction unites a broad set of disease features.

Slide 50 · Clinical triad: Ataxia-telangiectasia

Neurological

Early childhood ataxic-dyskinetic syndrome.

Vascular

Telangiectasias of conjunctivae and skin develop subsequently.

Immune

Immunodeficiency predisposes to recurrent respiratory infections.

Slide 51 · Early presentation: Instability and infections

Walking instability appears in early childhood.

Recurrent sinopulmonary infections are common initial manifestations.

Dysarthria and abnormal eye movements develop with disease progression.

Slide 52 · Telangiectasias add an extracerebellar diagnostic clue

Telangiectasias occur on the conjunctivae and skin.

They follow the onset of the early neurologic syndrome description.

Their presence supports a multisystem ataxia syndrome rather than an isolated motor disorder.

Slide 53 · Immunodeficiency carries clinical consequences

Defective immune function accompanies the neurological illness.

Repeated sinopulmonary infections are characteristic clinical problems.

Infectious symptoms may therefore appear alongside or before an obvious neurologic diagnosis.

Slide 54 · ATM: The central DNA-damage response

DNA injury

Double-strand break occurs

ATM kinase

Coordinates cellular detection and response signaling

Cell response

DNA-damage response pathways are orchestrated

The diagram simplifies ATM signaling; It does not specify unlisted molecular intermediates.

Slide 55 · ATM is a kinase with broad cellular responsibilities

ATM is encoded on chromosome 11q22–q23 in the source.

Its kinase product plays a critical role in responses to double-stranded DNA breaks.

The broader signaling network extends beyond canonical DNA repair.

Slide 56 · Additional processes influenced by ATM

Cell fate and genome

Apoptosis and telomere maintenance.

Stress and energy

Mitochondrial homeostasis and oxidative-stress responses.

Protein quality control

Ubiquitin–proteasomal degradation system.

Slide 57 · Why ATM loss causes neurodegeneration remains uncertain

ATM influences multiple cellular stress and maintenance pathways.

The pathway responsible for neuronal degeneration is unclear.

Defects of single-strand-break repair in other disorders produce comparable degeneration.

This resemblance supports a role for genome-maintenance biology but does not isolate one mechanism.

Slide 58 · Lymphoid neoplasia is an important association

Many individuals with ataxia-telangiectasia develop lymphoid neoplasms.

T-cell leukemias as particularly frequent among these cancers.

The neurodegenerative and hematologic manifestations fit a systemic DNA-response disorder.

Slide 59 · Ataxia-telangiectasia follows a progressive course

Early disease often features walking unsteadiness and recurrent infections.

Speech abnormalities and eye-movement abnormalities become apparent later.

The source describes relentless progression and death typically in early adulthood.

The stated course should be interpreted as a general textbook description.

Slide 60 · Compare the three major inherited patterns

Axis

Dominant SCAs

Friedreich ataxia

Ataxia-telangiectasia

Inheritance

Autosomal dominant

Autosomal recessive

Autosomal recessive

Molecular classes

PolyQ / noncoding / conventional

FXN GAA intronic expansion

ATM loss of function

Key clue

Highly variable; SCA7 vision

Neuropathy + cardiomyopathy

Telangiectasia + immunodeficiency

Mechanistic emphasis

Heterogeneous; often unresolved

Low frataxin → mitochondrial dysfunction

Deficient DNA-damage response

Slide 61 · Three mechanisms, three biological emphases

Abnormal protein

CAG/polyglutamine SCAs: Mutated proteins accumulate in neuronal nuclei.

Energy impairment

Friedreich ataxia: Frataxin deficiency compromises mitochondrial function.

Genome maintenance

Ataxia-telangiectasia: ATM loss affects DNA-break responses and other pathways.

Mechanistic categories guide understanding; They are not interchangeable diseases.

Slide 62 · Clinical reasoning: Onset and systemic clues

A school-aged child develops progressive gait ataxia, diminished tendon reflexes, an extensor plantar response, and impaired vibration sense. A cardiomyopathy is documented.

Dominant polyglutamine SCA

Friedreich ataxia

Ataxia-telangiectasia

Which source-supported syndrome best fits?

Slide 63 · Case interpretation: Friedreich ataxia

Early gait ataxia followed by motor progression matches the described chronology.

Loss of deep tendon reflexes with an extensor plantar response matches the characteristic examination.

Impaired vibration sense and cardiomyopathy reinforce the diagnosis.

The features are pattern-recognition clues; The source associates FRDA with FXN variants.

Slide 64 · Clinical reasoning: Neurologic plus immune disease

A young child has progressive unsteadiness and repeated sinopulmonary infections. Later, conjunctival vascular lesions appear, with dysarthria and eye-movement abnormalities.

Friedreich ataxia

Ataxia-telangiectasia

Spinocerebellar ataxia type 3

Which disorder unifies the neurological and systemic findings?

Slide 65 · Case interpretation: Ataxia-telangiectasia

Childhood unsteadiness and recurrent infections are characteristic early features.

Conjunctival telangiectasias and immunodeficiency distinguish the syndrome.

ATM dysfunction provides the disease’s molecular context.

Lymphoid neoplasia is an associated long-term concern.

Slide 66 · Clinical reasoning: Visual symptoms in dominant ataxia

Several generations in a family have progressive ataxia. One affected individual has prominent visual impairment in addition to the movement disorder.

SCA7 within the polyglutamine group

Ataxia-telangiectasia

Friedreich ataxia

Which Robbins-listed subtype offers a specific visual clue?

Slide 67 · Case interpretation: SCA7 and pattern matching

Autosomal-dominant family structure fits the SCA category.

SCA7 is specifically noted for associated visual impairment.

SCA7 appears’s CAG/polyglutamine disease list.

Genetic classification remains the appropriate framework for distinguishing numbered SCAs.

Slide 68 · What the provided textbook supports—and leaves open

Established: Shared neuronal targets, inherited classifications, named mutation categories.

Established: FXN/frataxin deficiency and ATM-mediated DNA-damage signaling are central molecular lesions.

Uncertain: Mechanisms underlying most noncoding-repeat SCAs and ATM-related neuronal degeneration.

Limitation: Source material alone does not justify subtype-specific diagnostic thresholds or treatment algorithms.

Slide 69 · Synthesis: recognize the disease family, then mechanism

Spinocerebellar degeneration names a pathological-anatomical family, not one disorder.

Dominant SCAs are genetically heterogeneous; coding and noncoding repeats must be distinguished.

Recessive Friedreich ataxia highlights mitochondrial and cardiometabolic pathology.

Recessive ataxia-telangiectasia links nervous-system degeneration with immune and DNA-response abnormalities.